WCC-2019 will provide a unique and ideal opportunity for a broad spectrum of researchers, clinicians and other health professionals to meet, discuss, share, learn and connect in order to find solutions to reduce the impact of cancer in the world. With the participation of outstanding international experts,
BIT's 12th Annual World Cancer Congress-2019（WCC-2019）will be held on May 15-17, 2019 in Osaka, Japan.
Given the major worldwide importance in cancer research, cancer therapies, and new drug trials, we should not only help ensure we’re apprised of current developments in the field but also reflect on new progress and look toward future challenges.
 |
Dr. Stefan Scherer, Senior Vice President of Clinical Development & Deputy Chief Medical Officer, CMO Cellectis, USA |  |
Dr. Vladimir Lazar, Chief Scientific and Operating Officer WIN Consortium, France |
 |
Dr. Margaret I. Fitch, Professor, University of Toronto, Canada |
 |
Dr. Tanya W. Moseley, Professor & Medical Director, Julie and Ben Rogers Breast Imaging Center, The University of Texas M.D. Anderson Cancer Center, USA |  |
Dr. Luzhe Sun, Professor, The University of Texas Health Science Center, USA |  |
Dr. Vinod K Prasad, Professor & Director of PBMT Fellowship Program, Duke University Medical Center, USA |
 |
Dr. Mahmoud Khalifa, The Donald F. Gleason Professor & Director, Masonic Cancer Center, University of Minnesota, USA |  |
Dr. Emil Toma, Full Clinical Professor, University of Montreal, Canada |  |
Dr. Tapan K. Bera, Associate Scientist, Laboratory of Molecular Biology, CCR, NCI, NIH, USA |
 |
Dr. Claudia Wagner, Associate Director, Immatics Biotechnologies GmbH, Germany |  |
Dr. Alexander A. Oraevsky, Chief Executive Officer & Chief Technology Officer, TomoWave Laboratories, Inc., USA |  |
Dr. Andre Tremblay, Professor, University of Montreal & Ste-Justine Hospital, Canada |
 |
Dr. Mark Paris, Director of Translational Applications, Mitra Biotech Inc., USA |  |
Dr. Philip Andrew Doble, Professor, University of Technology Sydney, Australia |  |
Dr. Corinne Isnard Bagnis, Professor, Pitie Salpetriere Hospital, France |
 |
Dr. Fumiaki Uchiumi, Professor, Tokyo University of Science, Japan |  |
Dr. Maria Marjorette O. Pena, Associate Professor & Director, Mouse Experimentation Core - Center for Colon Cancer Research, University of South Carolina, USA |  |
Dr. Xinjian Chen, Associate Professor, University of Utah School of Medicine, USA |
 |
Dr. Adolfo Cavalié, Professor, Experimental and Clinical Pharmacology and Toxicology, Saarland University, Germany |  |
Dr. Takahiro Miyazaki, Executive Director, Research Biology, Nektar Therapeutics, USA |  |
Dr. Ayako Wakatsuki Pedersen, Head of Translational Research, IO Biotech ApS, Denmark |
 |
Dr. Donatella Boschi, Associate Professor, University of Torino, Italy |  |
Dr. Arkadiusz Orzechowski, Professor, Warsaw University of Life Sciences – SGGW, Poland |  |
Dr. Kiven E. Lukong, Associate Professor, University of Saskatchewan, Canada |
 |
Dr. Beiyun Chen, Associate Professor, Mayo Clinic, USA |  |
Dr. Robyn A. Lindley, Associate Professor, The Victorian Comprehensive Cancer Centre, University of Melbourne, Australia |  |
Dr. Annette Byrne, Associate Professor, Royal College of Surgeons in Ire, Ireland |
As part of the 2019 World Cancer Congress, an exhibition space will provide a unique opportunity for exhibitors to showcase their products and services to participants with interests in all areas of cancer. Developed to offer comfort to delegates while maximizing exhibitor exposure, the coffee breaks and poster sessions will all take place in the exhibition area promoting frequent and repeated opportunities for delegates to visit the exhibits.
Exhibitors' advantages
• The exhibition will be visited by participants of the conference it means by your authentic target group from China and other countries.
• The exhibitors have the opportunity to present their exhibits more detailed, and have the opportunity for longer discussion with inquiring visitors – in most cases specialists – than during session discussions.
  |
Exhibition Date: |
BIT Group Global Ltd.
Japan-China Business Co., Ltd.
日中商務株式会社
Dr. Vladimir Lazar
Chief Scientific and Operating Officer
WIN Consortium, France
Dr. Ashok Srivastava
Chief Executive Officer & Chief Medical Officer, ClinFomatrix, Cure Pharmaceuticals, Inc, USA
Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2008-2019 BIT Congress Inc.